Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Starlite/ChEMBL | References |
Homo sapiens | ADAM metallopeptidase domain 17 | Starlite/ChEMBL | References |
Homo sapiens | matrix metallopeptidase 1 (interstitial collagenase) | Starlite/ChEMBL | References |
Homo sapiens | matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | adam 17 protease | Get druggable targets OG5_132656 | All targets in OG5_132656 |
Echinococcus granulosus | adam 17 protease | Get druggable targets OG5_132656 | All targets in OG5_132656 |
Schistosoma mansoni | ADAM17 peptidase (M12 family) | Get druggable targets OG5_132656 | All targets in OG5_132656 |
Echinococcus granulosus | Blood coagulation inhibitor Disintegrin | Get druggable targets OG5_132656 | All targets in OG5_132656 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132656 | All targets in OG5_132656 |
Schistosoma japonicum | ko:K06059 a disintegrin and metalloproteinase domain 17, putative | Get druggable targets OG5_132656 | All targets in OG5_132656 |
Echinococcus multilocularis | Blood coagulation inhibitor, Disintegrin | Get druggable targets OG5_132656 | All targets in OG5_132656 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Matrixin family protein | matrix metallopeptidase 1 (interstitial collagenase) | 403 aa | 401 aa | 27.7 % |
Brugia malayi | Disintegrin family protein | ADAM metallopeptidase domain 17 | 824 aa | 724 aa | 27.4 % |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | < 2.1 nM | In vitro inhibitory activity against broad spectrum matrix metalloproteinase-9 (MMP-9) | ChEMBL. | 12723945 |
Ki (binding) | < 2.1 nM | In vitro inhibitory activity against broad spectrum matrix metalloproteinase-9 (MMP-9) | ChEMBL. | 12723945 |
Ki (binding) | < 2.8 nM | In vitro inhibitory activity against broad spectrum matrix metalloproteinase-2 (MMP-2) | ChEMBL. | 12723945 |
Ki (binding) | < 2.8 nM | In vitro inhibitory activity against broad spectrum matrix metalloproteinase-2 (MMP-2) | ChEMBL. | 12723945 |
Ki (binding) | > 1000 nM | In vitro inhibitory activity against porcine tumor necrosis factor alpha converting enzyme (pTACE) | ChEMBL. | 12723945 |
Ki (binding) | > 1000 nM | In vitro inhibitory activity against porcine tumor necrosis factor alpha converting enzyme (pTACE) | ChEMBL. | 12723945 |
Ki (binding) | = 2019 nM | In vitro inhibitory activity against broad spectrum matrix metalloproteinase-1(MMP-1) | ChEMBL. | 12723945 |
Ki (binding) | = 2019 nM | In vitro inhibitory activity against broad spectrum matrix metalloproteinase-1(MMP-1) | ChEMBL. | 12723945 |
NT (functional) | In vitro ability compound to suppress the formation of TNF-aplha in human whole blood assay (WBA); NT means not tested | ChEMBL. | 12723945 | |
NT (functional) | Ability to suppress the formation of TNF-aplha in human peripheral blood mononuclear cell assay(PBMC). | ChEMBL. | 12723945 | |
NT (functional) | 0 | Ability to suppress the formation of TNF-aplha in human peripheral blood mononuclear cell assay(PBMC). | ChEMBL. | 12723945 |
NT (functional) | 0 | In vitro ability compound to suppress the formation of TNF-aplha in human whole blood assay (WBA); NT means not tested | ChEMBL. | 12723945 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.